Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 3/20 | 0.89 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.89 |
| ▸ | OXTR | P30559 | 2/20 | 0.89 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.89 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934390 | 1.00 | AVPR1A (0.89) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| SCHEMBL30525288 | 1.00 | AVPR1A (0.89) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| Vasopressin SCHEMBL18937546 | 0.94 | AVPR1A (1.00) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| Vasopressin SCHEMBL29688276 | 0.94 | AVPR1A (1.00) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| Vasopressin SCHEMBL19712236 | 0.94 | AVPR1A (1.00) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| Vasopressin SCHEMBL17874853 | 0.94 | AVPR1A (1.00) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.93 | AVPR1A (0.97) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| SCHEMBL23879427 | 0.92 | AVPR1A (0.96) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| SCHEMBL18476287 | 0.92 | AVPR1A (0.96) | AVPR1AAVPR2OXTRAVPR1BPTGS1 | |
| SCHEMBL29786906 | 0.92 | AVPR1A (0.74) | AVPR1AAVPR2OXTRAVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316143-A1 | THERAPEUTIC AGENTS AND/OR PHARMACEUTICAL COMPOSITIONS FOR NEUROCOGNITIVE DISORDERS | IMAMURA Jyunichi (JP) | 2024-09-26 | — | — | US | claimed |
| US-12478612-B2 | Deuterated domperidone compositions, methods, and preparation | CINDOME PHARMA, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240316143-A1 | THERAPEUTIC AGENTS AND/OR PHARMACEUTICAL COMPOSITIONS FOR NEUROCOGNITIVE DISORDERS | IMAMURA Jyunichi (JP) | 2024-09-26 | — | — | US | disclosed |
| WO-2024142211-A1 | THERAPEUTIC AGENT FOR DEMENTIA | 今村 純一 | 2024-07-04 | — | — | WO | disclosed |
| US-20240091199-A1 | Deuterated Domperidone Compositions, Methods, and Preparation | CINDOME PHARMA, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| CN-116712432-A | Deuterated domperidone compositions, methods and preparations | 辛多美制药有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-111093653-B | Deuterated domperidone compositions, methods and preparations | 辛多美制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11364226-B2 | Deuterated domperidone compositions, methods, and preparation | CINRX PHARMA, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| CN-113995755-A | Deuterated domperidone composition and method for treating disorders | 辛多美制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091199-A1 | Deuterated Domperidone Compositions, Methods, and Preparation | DRD2, DRD1, DRD4 | AVPR1A 43/4885AVPR2 11/4885OXTR 250/4885 |
| US-20240316143-A1 | THERAPEUTIC AGENTS AND/OR PHARMACEUTICAL COMPOSITIONS FOR NEUROCOGNITIVE DISORDERS | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885AVPR2 2/4885OXTR 30/4885 |
| US-11364226-B2 | Deuterated domperidone compositions, methods, and preparation | DRD2, DRD1, DRD4 | AVPR1A 43/4885AVPR2 11/4885OXTR 250/4885 |
| US-12478612-B2 | Deuterated domperidone compositions, methods, and preparation | DRD2, DRD1, DRD4 | AVPR1A 43/4885AVPR2 11/4885OXTR 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.